References

10.1002/jia2.26072

10.1002/jia2.26072 · External reference

Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living with HIV Monoinfection: A Systematic Review and Meta‐Analysis

10.1016/j.cgh.2023.01.001 · 2023 · External reference

10.1002/jia2.26238

10.1002/jia2.26238 · External reference

10.1002/hep4.1134

10.1002/hep4.1134 · External reference

10.1111/j.1365‐2036.2011.04724.x

10.1111/j.1365‐2036.2011.04724.x · External reference

10.1056/nejmra1503519

10.1056/nejmra1503519 · External reference

10.1016/j.jhep.2017.05.011

10.1016/j.jhep.2017.05.011 · External reference

10.3748/wjg.v24.i42.4728

10.3748/wjg.v24.i42.4728 · External reference

10.1038/s41575‐018‐0085‐7

10.1038/s41575‐018‐0085‐7 · External reference

10.1086/505495

10.1086/505495 · External reference

10.1097/01.aids.0000163935.99401.25

10.1097/01.aids.0000163935.99401.25 · External reference

Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus

10.1016/j.cgh.2020.10.018 · 2022 · External reference

10.1038/ajg.2014.32

10.1038/ajg.2014.32 · External reference

10.1086/589294

10.1086/589294 · External reference

10.1002/jia2.25201

10.1002/jia2.25201 · External reference

A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature

2023 · External reference

10.1097/01.qai.0000221683.44940.62

10.1097/01.qai.0000221683.44940.62 · External reference

10.1021/bi035596s

10.1021/bi035596s · External reference

10.1086/427655

10.1086/427655 · External reference

10.1097/qad.0b013e32832b4377

10.1097/qad.0b013e32832b4377 · External reference

10.1002/hep.23647

10.1002/hep.23647 · External reference

Hepatic Steatosis and Steatohepatitis in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients

10.1002/hep.25791 · 2012 · External reference

10.1097/00002030‐199807000‐00003

10.1097/00002030‐199807000‐00003 · External reference

10.1097/00002030‐200411050‐00005

10.1097/00002030‐200411050‐00005 · External reference

10.1097/qad.0000000000001495

10.1097/qad.0000000000001495 · External reference

10.1097/qai.0000000000001525

10.1097/qai.0000000000001525 · External reference

10.1002/jia2.25484

10.1002/jia2.25484 · External reference

10.1093/cid/ciaf049

10.1093/cid/ciaf049 · External reference

Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus–Infected Patients With Nonalcoholic Fatty Liver Disease

10.1093/cid/cix467 · 2017 · External reference

10.1053/j.gastro.2010.11.052

10.1053/j.gastro.2010.11.052 · External reference

Sentinel Research Network (SRN) of IeDEA: Study Protocol [Internet]

2020 · External reference

Unresolved reference

External reference

Appropriate Body‐Mass Index for Asian Populations and Its Implications for Policy and Intervention Strategies

10.1016/s0140-6736(03)15268-3 · 2004 · External reference

Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity

10.1161/circulationaha.109.192644 · 2009 · External reference

10.1001/jama.289.19.2560

10.1001/jama.289.19.2560 · External reference

Unresolved reference

External reference

10.7326/aitc201712050

10.7326/aitc201712050 · External reference

10.1177/2050640619900820

10.1177/2050640619900820 · External reference

10.1097/qad.0000000000000841

10.1097/qad.0000000000000841 · External reference

10.1016/j.jhep.2016.12.022

10.1016/j.jhep.2016.12.022 · External reference

Missing Data Imputation: Focusing on Single Imputation

2016 · External reference

10.1002/jia2.25899

10.1002/jia2.25899 · External reference

10.1002/jia2.26371

10.1002/jia2.26371 · External reference

10.1002/hep.28431

10.1002/hep.28431 · External reference

10.1016/j.jhep.2008.11.017

10.1016/j.jhep.2008.11.017 · External reference

Burden of Metabolic Syndrome in the Global Adult HIV‐Infected Population: A Systematic Review and Meta‐Analysis

10.1186/s12889-024-20118-3 · 2024 · External reference

Stratifying the Risk of NAFLD in Patients With HIV Under Combination Antiretroviral Therapy (cART)

10.1016/j.eclinm.2021.101116 · 2021 · External reference

10.1016/j.metabol.2018.11.014

10.1016/j.metabol.2018.11.014 · External reference

Association of Adipose Tissue Inflammation With Histologic Severity of Nonalcoholic Fatty Liver Disease

10.1053/j.gastro.2015.05.044 · 2015 · External reference

10.1053/j.gastro.2018.06.031

10.1053/j.gastro.2018.06.031 · External reference

10.1002/hep.23280

10.1002/hep.23280 · External reference

Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes

10.1016/s1542-3565(04)00014-x · 2004 · External reference

10.1007/s10620‐013‐2743‐5

10.1007/s10620‐013‐2743‐5 · External reference

Risk of Severe Liver Disease in Nonalcoholic Fatty Liver Disease With Normal Aminotransferase Levels: A Role for Insulin Resistance and Diabetes

10.1002/hep.22429 · 2008 · External reference

10.1016/j.jhep.2014.12.012

10.1016/j.jhep.2014.12.012 · External reference

10.1042/cs20080253

10.1042/cs20080253 · External reference

10.1016/s2213‐8587(14)70032‐4

10.1016/s2213‐8587(14)70032‐4 · External reference

10.3390/ijms21176275

10.3390/ijms21176275 · External reference

10.1097/qad.0000000000003903

10.1097/qad.0000000000003903 · External reference

10.1042/cs20220572

10.1042/cs20220572 · External reference

Dolutegravir With Emtricitabine and Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate Versus Efavirenz, Emtricitabine, and Tenofovir Disoproxil Fumarate for Initial Treatment of HIV‐1 Infection (ADVANCE): Week 96 Results From a Randomised, Phase 3, Non‐Inferiority Trial

10.1016/s2352-3018(20)30241-1 · 2020 · External reference

10.1093/cid/ciab444

10.1093/cid/ciab444 · External reference

10.1093/cid/ciz999

10.1093/cid/ciz999 · External reference